Goldman Sachs Group Inc Cerevel Therapeutics Holdings, Inc. Transaction History

Goldman Sachs Group Inc

$613 Billion
Q4 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$38.96 - $42.75 $153,697 - $168,648	3,945 Added 0.39%	1,020,921 $41.7 Million
Q1 2024 May 15, 2024	BUY	$40.88 - $43.27 $19.8 Million - $21 Million	484,219 Added 90.89%	1,016,976 $43 Million
Q4 2023 Feb 13, 2024	BUY	$20.27 - $42.44 $4.22 Million - $8.84 Million	208,258 Added 64.18%	532,757 $22.6 Million
Q3 2023 May 14, 2024	SELL	$20.26 - $31.91 $4.22 Million - $6.65 Million	-208,258 Reduced 39.09%	324,499 $7.08 Million
Q3 2023 Nov 14, 2023	SELL	$20.26 - $31.91 $794,293 - $1.25 Million	-39,205 Reduced 10.78%	324,499 $7.08 Million
Q2 2023 May 14, 2024	SELL	$23.9 - $35.38 $319,136 - $472,429	-13,353 Reduced 3.54%	363,704 $11.6 Million
Q2 2023 Aug 14, 2023	SELL	$23.9 - $35.38 $319,136 - $472,429	-13,353 Reduced 3.54%	363,704 $11.6 Million
Q1 2023 May 14, 2024	BUY	$22.82 - $35.32 $1.6 Million - $2.48 Million	70,107 Added 22.84%	377,057 $9.2 Million
Q1 2023 May 11, 2023	BUY	$22.82 - $35.32 $1.6 Million - $2.48 Million	70,107 Added 22.84%	377,057 $9.2 Million
Q4 2022 May 14, 2024	BUY	$25.35 - $31.96 $1.55 Million - $1.95 Million	61,153 Added 24.88%	306,950 $9.68 Million
Q4 2022 Feb 13, 2023	BUY	$25.35 - $31.96 $1.55 Million - $1.95 Million	61,153 Added 24.88%	306,950 $9.68 Million
Q3 2022 May 14, 2024	BUY	$25.5 - $41.42 $3.69 Million - $5.99 Million	144,693 Added 143.11%	245,797 $6.95 Million
Q3 2022 Nov 10, 2022	BUY	$25.5 - $41.42 $3.69 Million - $5.99 Million	144,693 Added 143.11%	245,797 $6.95 Million
Q2 2022 May 14, 2024	SELL	$20.62 - $37.15 $8.9 Million - $16 Million	-431,653 Reduced 81.02%	101,104 $2.67 Million
Q2 2022 Aug 15, 2022	BUY	$20.62 - $37.15 $388,460 - $699,868	18,839 Added 22.9%	101,104 $2.67 Million
Q1 2022 May 16, 2022	SELL	$23.5 - $35.38 $7.98 Million - $12 Million	-339,423 Reduced 80.49%	82,265 $2.88 Million
Q4 2021 Feb 14, 2022	SELL	$29.21 - $44.64 $2.57 Million - $3.93 Million	-88,059 Reduced 17.28%	421,688 $13.7 Million
Q3 2021 Nov 10, 2021	BUY	$21.26 - $38.85 $10.8 Million - $19.8 Million	509,747 New	509,747 $15 Million

Others Institutions Holding CERE

# of Institutions

Shares Held

5.01M

Call Options Held

3.3K

Put Options Held

View Full List

About Cerevel Therapeutics Holdings, Inc.

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

More about CERE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account